4303 Highlights of This Issue

4305 SPECIAL FEATURES

Editorial

4305 Food and Oral Antineoplastics: More Than Meets the Eye
Rajul K. Jain, Satjit S. Brar, and Lawrence J. Lesko
See article p. 4446

4308 CCR Translations

4308 Personalized Tamoxifen: A Step Closer but Miles To Go
Aditya Bardia and Vered Stearns
See article p. 4468

4311 Arsenic Trioxide and the Phosphoinositide 3-Kinase/Akt Pathway in Chronic Lymphocytic Leukemia
Dennis J. Goussotis and Leonidas C. Platanias
See article p. 4382

4313 CCR New Strategies

4313 New Strategies in Pancreatic Cancer: Emerging Epidemiologic and Therapeutic Concepts
Donghui Li and James L. Abbruzzese

4319 Molecular Pathways

4319 Overcoming Persistent Dependency on Androgen Signaling after Progression to Castration-Resistant Prostate Cancer
Masuo Yamaoka, Takahito Hara, and Masami Kusaka

4325 PI(3)King Apart PTEN's Role in Cancer
Siyuan Zhang and Dihua Yu

4331 Report from the FDA

4331 U.S. Food and Drug Administration Approval: Ofatumumab for the Treatment of Patients with Chronic Lymphocytic Leukemia Refractory to Fludarabine and Alemtuzumab
Steven J. Lemery, Jenny Zhang, Mark D. Rothmann, Jun Yang, Justin Earp, Hong Zhao, Andrew McDougal, Anne Pilano, Raymond Chiang, Joseph E. Gootenberg, Patricia Keegan, and Richard Pazdur

4339 HUMAN CANCER BIOLOGY

4339 Transcriptional Profiling of Polycythemia Vera Identifies Gene Expression Patterns Both Dependent and Independent from the Action of JAK2V617F
Windy Berkofofsky-Fessler, Monica Buzzai, Marianne K-H. Kim, Steven Fruchtmann, Vesna Najfeld, Dong-Joon Min, Fabricio F. Costa, Jared M. Bischof, Marcelo B. Soares, Melanie Jane Mcconnell, Weijia Zhang, Ross Levine, D. Gary Gilliland, Raffaele Calogero, and Jonathan D. Licht

4353 Meta-analysis of Neuroblastomas Reveals a Skewed ALK Mutation Spectrum in Tumors with MYCN Amplification
Sara De Brouwer, Katleen De Preter, Candy Kumps, Piotr Zabrocki, Michael Porcu, Ellen M. Westerhout, Arjan Lakeman, Jo Vandesompele, Jasmien Hoebeeck, Tom Van Maerken, Anne De Paepe, Genevieve Laureys, Johannes H. Schulte, Alexander Schramm, Caroline Van Den Broecke, Joëlle Vermeulen, Nadine Van Roy, Klaus Beiske, Marleen Renard, Rosa Noguera, Olivier Delattre, Isabelle Janoueix-Lerosey, Per Kogner, Tommy Martinsson, Akira Nakagawara, Miki Ohira, Huib Caron, Angelika Eggert, Jan Cools, Rogier Versteeg, and Frank Speleman

4363 Upregulation of SOX9 in Lung Adenocarcinoma and Its Involvement in the Regulation of Cell Growth and Tumorigenicity
Shih Sheng Jiang, Wen-Tsen Fang, Ya-Hsue Hou, Shiu-Feng Huang, B. Linju Yen, Jinn-Kiang Chang, Shih-Miao Li, Hui-Ping Liu, Ying-Lan Liu, Chih-Ting Huang, Yu-Wei Li, Te-Hsuan Iang, Shih-Hsuan Chan, Su Jing Yang, Chao A. Hsiung, Cheng-Wen Wu, Lu-Hai Wang, and I-Shou Chang
The Relationship between Prostate-Specific Antigen and Prostate Cancer Risk: The Prostate Biopsy Collaborative Group


Notch1 Expression Predicts an Unfavorable Prognosis and Serves as a Therapeutic Target of Patients with Neuroblastoma

Hsiu-Hao Chang, Hsinyu Lee, Ming-Kuan Hu, Po-Nien Tsao, Hsueh-Fen Juan, Min-Chuan Huang, Yu-Yin Shih, Bo-Jeng Wang, Yung-Ming Jen, Christina Ling Chang, Shiu-Feng Huang, Yeou-Guang Tsay, Fon-Jou Hsieh, Kai-Hsin Lin, Wen-Ming Hsu, and Yung-Feng Liao

Prediction of Stage, Grade, and Survival in Bladder Cancer Using Genome-wide Expression Data: A Validation Study

Martin Lauss, Markus Ringnér, and Mattias Höglund

Preclinical and Clinical Evidence that Deoxy-2-[18F]fluoro-D-glucose Positron Emission Tomography with Computed Tomography Is a Reliable Tool for the Detection of Early Molecular Responses to Erlotinib in Head and Neck Cancer

Sébastien Vergez, Jean-Pierre Delord, Fabienne Thomas, Philippe Rochaix, Olivier Caselles, Thomas Filleron, Séverine Brillouet, Pierre Canal, Frédéric Courbon, and Ben C. Allal

Inconsistent Labeling of Food Effect for Oral Agents across Therapeutic Areas: Differences between Oncology and Non-Oncology Products

Soonmo Peter Kang and Mark J. Ratain

See commentary p. 4305

Histopathologic and Immunohistochemical Characterization of Rash to Human Epidermal Growth Factor Receptor 1 (HER1) and HER1/2 Inhibitors in Cancer Patients

Beatrice Nardone, Kimberly Nicholson, Marissa Newman, Joan Guitart, Pedram Gerami, Nicholas Talarioc, Ximing J. Yang, Alfred Rademaker, Dennis P. West, and Mario E. Lacouture

Actinomycin D Decreases Mcl-1 Expression and Acts Synergistically with ABT-737 against Small Cell Lung Cancer Cell Lines

Haishan Xu and Geoffrey W. Krystal

Histopathologic and Immunohistochemical Characterization of Rash to Human Epidermal Growth Factor Receptor 1 (HER1) and HER1/2 Inhibitors in Cancer Patients

Beatrice Nardone, Kimberly Nicholson, Marissa Newman, Joan Guitart, Pedram Gerami, Nicholas Talarioc, Ximing J. Yang, Alfred Rademaker, Dennis P. West, and Mario E. Lacouture

Neurotensin Receptor 1 Determines the Outcome of Non–Small Cell Lung Cancer

Marco Alifano, Frédérique Souazé, Sandra Dupouy, Sophie Camilleri-Broët, Mohamad Younes, Sadi-Menad Ahmed-Zaïd, Takashi Takahashi, Alessandra Cancellieri, Stefania Damiani, Maurizio Boaron, Philippe Broët, Lance D. Miller, Christian Gespach, Jean François Regnard, and Patricia Forgez

Notch1 Expression Predicts an Unfavorable Prognosis and Serves as a Therapeutic Target of Patients with Neuroblastoma

Hsiu-Hao Chang, Hsinyu Lee, Ming-Kuan Hu, Po-Nien Tsao, Hsueh-Fen Juan, Min-Chuan Huang, Yu-Yin Shih, Bo-Jeng Wang, Yung-Ming Jen, Christina Ling Chang, Shiu-Feng Huang, Yeou-Guang Tsay, Fon-Jou Hsieh, Kai-Hsin Lin, Wen-Ming Hsu, and Yung-Feng Liao

Prediction of Stage, Grade, and Survival in Bladder Cancer Using Genome-wide Expression Data: A Validation Study

Martin Lauss, Markus Ringnér, and Mattias Höglund

Preclinical and Clinical Evidence that Deoxy-2-[18F]fluoro-D-glucose Positron Emission Tomography with Computed Tomography Is a Reliable Tool for the Detection of Early Molecular Responses to Erlotinib in Head and Neck Cancer

Sébastien Vergez, Jean-Pierre Delord, Fabienne Thomas, Philippe Rochaix, Olivier Caselles, Thomas Filleron, Séverine Brillouet, Pierre Canal, Frédéric Courbon, and Ben C. Allal

Inconsistent Labeling of Food Effect for Oral Agents across Therapeutic Areas: Differences between Oncology and Non-Oncology Products

Soonmo Peter Kang and Mark J. Ratain

See commentary p. 4305

Histopathologic and Immunohistochemical Characterization of Rash to Human Epidermal Growth Factor Receptor 1 (HER1) and HER1/2 Inhibitors in Cancer Patients

Beatrice Nardone, Kimberly Nicholson, Marissa Newman, Joan Guitart, Pedram Gerami, Nicholas Talarioc, Ximing J. Yang, Alfred Rademaker, Dennis P. West, and Mario E. Lacouture

Neurotensin Receptor 1 Determines the Outcome of Non–Small Cell Lung Cancer

Marco Alifano, Frédérique Souazé, Sandra Dupouy, Sophie Camilleri-Broët, Mohamad Younes, Sadi-Menad Ahmed-Zaïd, Takashi Takahashi, Alessandra Cancellieri, Stefania Damiani, Maurizio Boaron, Philippe Broët, Lance D. Miller, Christian Gespach, Jean François Regnard, and Patricia Forgez

Notch1 Expression Predicts an Unfavorable Prognosis and Serves as a Therapeutic Target of Patients with Neuroblastoma

Hsiu-Hao Chang, Hsinyu Lee, Ming-Kuan Hu, Po-Nien Tsao, Hsueh-Fen Juan, Min-Chuan Huang, Yu-Yin Shih, Bo-Jeng Wang, Yung-Ming Jen, Christina Ling Chang, Shiu-Feng Huang, Yeou-Guang Tsay, Fon-Jou Hsieh, Kai-Hsin Lin, Wen-Ming Hsu, and Yung-Feng Liao

Prediction of Stage, Grade, and Survival in Bladder Cancer Using Genome-wide Expression Data: A Validation Study

Martin Lauss, Markus Ringnér, and Mattias Höglund

Preclinical and Clinical Evidence that Deoxy-2-[18F]fluoro-D-glucose Positron Emission Tomography with Computed Tomography Is a Reliable Tool for the Detection of Early Molecular Responses to Erlotinib in Head and Neck Cancer

Sébastien Vergez, Jean-Pierre Delord, Fabienne Thomas, Philippe Rochaix, Olivier Caselles, Thomas Filleron, Séverine Brillouet, Pierre Canal, Frédéric Courbon, and Ben C. Allal

Inconsistent Labeling of Food Effect for Oral Agents across Therapeutic Areas: Differences between Oncology and Non-Oncology Products

Soonmo Peter Kang and Mark J. Ratain

See commentary p. 4305

Histopathologic and Immunohistochemical Characterization of Rash to Human Epidermal Growth Factor Receptor 1 (HER1) and HER1/2 Inhibitors in Cancer Patients

Beatrice Nardone, Kimberly Nicholson, Marissa Newman, Joan Guitart, Pedram Gerami, Nicholas Talarioc, Ximing J. Yang, Alfred Rademaker, Dennis P. West, and Mario E. Lacouture
The Effectiveness of Off-Protocol Adjuvant Chemotherapy for Patients with Urothelial Carcinoma of the Urinary Bladder

CYP2D6 Polymorphisms as Predictors of Outcome in Breast Cancer Patients Treated with Tamoxifen: Expanded Polymorphism Coverage Improves Risk Stratification
Werner Schroth, Ute Hamann, Peter A. Fasching, Silke Dauser, Stefan Winter, Michel Eichelbaum, Matthias Schwab, and Hiltrud Brauch

Preclinical and Clinical Estimates of the Basal Apoptotic Rate of a Cancer Predict the Amount of Apoptosis Induced by Subsequent Proapoptotic Stimuli
Lian Zhang, Brian D. Kavanagh, Andrew M. Thorburn, and D. Ross Camidge

Correction: Biobehavioral, Immune, and Health Benefits following Recurrence for Psychological Intervention Participants
See commentary p. 4308

ABOUT THE COVER
This is an original study providing, from preclinical models to patients, a reliable proof of 18FDG-PET/CT efficiency as a surrogate marker for the early evaluation of EGFR-TKI (erlotinib) efficacy that may improve diagnostic accuracy of molecular effect (ERK1/2). The image represents a facial sagittal section of an 18FDG-PET/CT of a patient with an oropharyngeal head and neck squamous cell carcinoma. It reveals a tumor 18FDG uptake before patient exposure to erlotinib. For further details, please see the article by Vergez and colleagues on page 4434 of this issue.